Oncology drug repurposing—identifying new therapeutic indications for existing non-cancer medications—has emerged as a major area of investigation to overcome the limitations, high costs, and toxicities of conventional cancer care.
Because generic, off-patent drugs have established human safety profiles and known manufacturing pipelines, repurposing offers an accelerated route to target cancer bioenergetics, drug resistance, and cancer stem cell (CSC) populations.
1. Key Repurposed Candidates & Mechanisms of Action
Research in this field centers primarily on antiparasitic compounds that demonstrate multi-targeted cytotoxic and metabolic properties across preclinical tumor models:
Benzimidazoles (Mebendazole & Fenbendazole):
Microtubule Disruption: Bind \(\beta\)-tubulin at the colchicine-binding site to destabilize microtubules, causing \(G_2/M\) cell cycle arrest and mitotic catastrophe (similar to vinca alkaloids and taxanes).
Warburg Effect Blockade: Downregulate glucose transporters (GLUT1/4) and hexokinase II (HKII), starving glycolytically dependent tumor cells.
Apoptosis & Stress Cascades: Stabilize p53, downregulate Mdm2/MdmX, impair proteasomal degradation, increase intracellular reactive oxygen species (ROS), and trigger caspase-mediated apoptosis, pyroptosis, and ferroptosis.
P-gp Independence: Are neither substrates nor inhibitors of P-glycoprotein (P-gp) efflux pumps, allowing them to retain activity in multidrug-resistant cell lines.
Compound Differences: Mebendazole is FDA-approved for human use, possesses known oral safety data, and crosses the blood-brain barrier. Fenbendazole is a veterinary anthelmintic that lacks formal human regulatory approval but underpins widely discussed patient protocols (e.g., the Joe Tippens protocol).
Macrocyclic Lactones (Ivermectin):
Multi-Pathway Suppression: Downregulates master oncogenic cascades including Wnt/\(\beta\)-catenin, Akt/mTOR, STAT3, and PAK1.
Cancer Stem Cell (CSC) Elimination: Selectively targets quiescent, self-renewing cancer stem cell populations to inhibit tumor initiation, invasion, and recurrence.
Immune Microenvironment & P-gp Blockade: Promotes purinergic P2X7-mediated immunogenic cell death, turning immunologically “cold” tumors into “hot” tumors receptive to immune checkpoint inhibitors. Inhibits P-gp efflux pumps to reverse chemotherapy resistance.
Other Notable Repurposed Agents:
Niclosamide: Demonstrates broad pathway inhibition (Wnt/\(\beta\)-catenin, STAT3, Notch, mTORC1) and mitochondrial uncoupling, but its clinical development is hindered by poor oral bioavailability.
Atovaquone: Inhibits mitochondrial complex III, reducing cellular oxygen consumption to alleviate tumor hypoxia—a primary driver of radiation and chemotherapy resistance.
2. Clinical Evidence & Oxford CEBM Hierarchy
The evidence supporting repurposed antiparasitics spans a spectrum from laboratory research to early-phase clinical trials:
Preclinical Foundation: Extensive in vitro and animal xenograft data demonstrate single-agent and synergistic antitumor activity across more than 20 malignancy types (breast, lung, glioblastoma, colorectal, prostate, lymphoma, leukemia, and renal cell carcinoma).
Observational Cohorts & Case Registries:
760+ Case Compilation: Publicly assembled archives document anecdotal accounts of complete remissions, tumor debulking, and circulating tumor DNA (ctDNA) clearance across 30+ cancer subtypes.
The METRICS Study: A retrospective glioblastoma cohort evaluating a 4-drug adjunctive metabolic protocol (mebendazole 100 mg/day, metformin, atorvastatin, and doxycycline) alongside standard chemoradiation reported an extended median overall survival of ~27 months vs. ~15 months in historical controls.
Hulscher et al. (2026) Cohort: A prospective observational study of 197 cancer patients receiving compounded ivermectin (25 mg) and mebendazole (250 mg) reported an 84.4% clinical benefit rate (no evidence of disease, tumor shrinkage, or stable disease) among 122 patients completing 6-month follow-up.
Oxford Centre for Evidence-Based Medicine (CEBM) Grading:
Mebendazole & Niclosamide: CEBM Level 2 (supported by small, early-phase Phase I/II clinical trials with mixed/inconclusive pharmacokinetic signals).
Ivermectin & Fenbendazole: CEBM Level 3–4 (supported primarily by case series, observational cohorts, and mechanistic models).
Note: No repurposed antiparasitic has reached Level 1 randomized controlled trial (RCT) validation for a cancer indication.
3. Primary Research Challenges & Methodological Barriers
Despite strong preclinical rationales, several critical obstacles complicate the evaluation of repurposed drugs:
Causal Ambiguity & Treatment Synergy: About 70% to 80% of documented “success stories” involve patients taking repurposed drugs alongside standard chemotherapy, radiation, targeted therapy, or immunotherapy. Consequently, these observations support a treatment synergy or chemosensitization hypothesis rather than proving standalone drug efficacy.
The Bioavailability & Pharmacokinetic Gap: Cytotoxic concentrations demonstrated in cell culture often exceed achievable human plasma or tissue levels at standard antiparasitic doses.
Publication, Selection, & Data Integrity Biases: Social media registries naturally suffer from survivorship and reporting bias (capturing positive outcomes while omitting non-responders or fatal cases). Furthermore, prominent observational studies and case series in this domain have faced journal Expressions of Concern or retractions over ethical and data-verification issues.
Lack of Commercial Incentive: Because these generic agents are off-patent, pharmaceutical companies lack financial incentives to fund costly Phase III randomized controlled trials.
4. Regulatory Stance, Safety, & Research Roadmap
ASCO Clinical Guidelines: The American Society of Clinical Oncology (ASCO) issued a formal Clinical Notice cautioning against self-administering ivermectin or fenbendazole for cancer outside well-designed clinical trials, citing unproven human efficacy and potential risks of toxicity or drug interactions.
Safety & Toxicity Monitoring: Long-term off-label use requires baseline and ongoing liver function monitoring (ALT, AST, bilirubin) due to documented risks of drug-induced liver injury. Additionally, ivermectin is metabolized via CYP3A4 and acts as a P-gp substrate, creating potential drug-drug interactions with blood thinners (e.g., warfarin) and hepatically cleared chemotherapeutics.
Translational Roadmap: Researchers emphasize that bridging the gap between anecdotal signals and clinical acceptance requires structured prospective registries, formal pharmacokinetic/pharmacodynamic studies, and randomized Phase II/III combination trials.
Chiang, R. H., et al. (2021). Fenbendazole enhancing antitumor effect: A case series of complete remission in advanced genitourinary cancers. [Medical Case Series Report].
Ellison, A. (2026). Fenbendazole for lung cancer: Research review 2026. TroubleFree Cancer Research Review. https://fenbendazole-lung-cancer-review-2026.org
Integrative Oncology Research Group. (2025). Fenbendazole and ivermectin for cancer: Real stories, science & protocols (2025 Guide, Reference Edition 1). Evidence-Tiered Reference Guide.
Integrative Oncology Research Group. (2025). Fenbendazole and ivermectin for cancer: Real stories, science & protocols (2025 Guide, Reference Edition 2). Evidence-Tiered Reference Guide.
Makis, W. (2026). Fenbendazole, ivermectin and mebendazole for cancer: Case series of 760+ case reports (September 2026 Update). Patient-Driven Research Registry.
Makis, W. (2026). Ivermectin and mebendazole as adjunctive therapy in high-grade glioma and other intracranial tumors: A retrospective compilation of publicly reported cases. Clinical Neuro-Oncology Archive.
Makis, W. (2026). Ivermectin, fenbendazole and mebendazole in lymphoma and leukemia: 43 case reports/series (August 2026 Update). Hematologic Oncology Case Archive.
Makis, W. (2026). Ivermectin, mebendazole and fenbendazole for breast cancer: A case series of 132 case reports (September 2026 Update). Integrative Breast Oncology Case Series.
Makis, W. (2026). Ivermectin, mebendazole and fenbendazole for breast cancer: A structured case-series analysis of 130 reports. Breast Cancer Research Registry.
With the study of compounded ivermectin (25 mg) and mebendazole (250 mg) reported an 84.4% clinical benefit rate (no evidence of disease, tumor shrinkage, or stable disease) among 122 patients completing 6-month follow-up. Did they cycle off after 21 days and cycle back on or was it a continuous 6 months?